Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07290569 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Oruka Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT07290569: Recruiting Phase 2 study of Plaque Psoriasis, sponsored by Oruka Therapeutics.
NCT07290569 is a Phase 2 study of Plaque Psoriasis that is actively recruiting participants, run by Oruka Therapeutics. The registered enrollment target is 160 participants, below the 412-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07290569, a Phase 2 study of Plaque Psoriasis, is actively recruiting participants, sponsored by Oruka Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Primary Outcome
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG ORKA-001
Study Locations (20)
Texas
- Oruka Therapeutics Investigative Site - Frisco
- Oruka Therapeutics Investigative Site - Houston
- Oruka Therapeutics Investigative Site - Webster
California
- Oruka Therapeutics Investigative Site - Los Angeles
- Oruka Therapeutics Investigative Site - Los Angeles
Ohio
- Oruka Therapeutics Investigative Site - Cleveland
- Oruka Therapeutics Investigative Site - Mason
Oregon
- Oruka Therapeutics Investigative Site - Portland
- Oruka Therapeutics Investigative Site - Portland
Arizona
- Oruka Therapeutics Investigative Site - Phoenix
Arkansas
- Oruka Therapeutics Investigative Site - North Little Rock
Florida
- Oruka Therapeutics Investigative Site - Coral Gables
Illinois
- Oruka Therapeutics Investigative Site - Rolling Meadows
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT07290569 shows while recruiting
NCT07290569 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 412-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07290569 names 20 study sites across 15 states, led by Texas, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT07290569 about?
NCT07290569 is a clinical study titled "Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis". This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT07290569?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-12-03. Estimated completion is 2028-12.
What conditions does trial NCT07290569 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT07290569?
The interventions under investigation include: Placebo (OTHER), ORKA-001 (DRUG).
Who is sponsoring clinical trial NCT07290569?
This trial is sponsored by Oruka Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07290569 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07290569's enrollment target sits among peer trials
160 24th of 45 higher than 22 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
-
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI